Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$0.6994
−$0.0141 · -1.98%
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Regular session
$0.6994
−$0.0141 · -1.98%
Regular session · ET · Market data may be delayed.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Day range
Current $0.6994
52-week range
Current $0.6994
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
69
Undervalued
Sentiment
57
Mixed
Risk
66
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Day range
Current $0.6994
52-week range
Current $0.6994
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 107.88M USD | 90.05M USD | 70.19M USD | 37.05M USD | 22.24M USD |
| Cost of goods sold | 43.43M USD | 34.91M USD | 26.26M USD | 17.84M USD | 11.68M USD |
| Gross profit | 64.44M USD | 55.14M USD | 43.93M USD | 19.22M USD | 10.56M USD |
| Research and development | 10.35M USD | 10.55M USD | 6.38M USD | 7.56M USD | 5.59M USD |
| Selling, general, and administrative | 66.75M USD | 61.4M USD | 59.93M USD | 50.12M USD | 30.22M USD |
| Operating expenses | 79.84M USD | 79.86M USD | 71.26M USD | 57.12M USD | 37.41M USD |
| Interest income | 1.5M USD | 1.08M USD | 1.09M USD | 125K USD | 11K USD |
| Interest expense | 12.16M USD | 7.63M USD | 5.77M USD | 2.74M USD | 1.88M USD |
| Depreciation and amortization | 9.21M USD | 8.04M USD | 6.86M USD | 4.91M USD | 3.04M USD |
| Operating income | −15.4M USD | −24.72M USD | −27.33M USD | −37.9M USD | −26.84M USD |
| Net income | −33.52M USD | −38.07M USD | −43.1M USD | −44.04M USD | −29M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.50
257.45% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 14, 2023 | 1:10 | — | — |
Effective Nov 14, 2023
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
